Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 725379 | https://doi.org/10.1155/2015/725379

Meng-Tsz Tsai, Ching-Yi Chen, Yu-Hui Pan, Siou-Huei Wang, Harry J. Mersmann, Shih-Torng Ding, "Alleviation of Carbon-Tetrachloride-Induced Liver Injury and Fibrosis by Betaine Supplementation in Chickens", Evidence-Based Complementary and Alternative Medicine, vol. 2015, Article ID 725379, 12 pages, 2015. https://doi.org/10.1155/2015/725379

Alleviation of Carbon-Tetrachloride-Induced Liver Injury and Fibrosis by Betaine Supplementation in Chickens

Academic Editor: Yuewen Gong
Received09 Jun 2015
Revised28 Aug 2015
Accepted02 Sep 2015
Published27 Sep 2015


Betaine is a food component with well-reported hepatoprotection effects. However, the effects and mechanisms of betaine on liver fibrosis development are still insufficient. Because metabolic functions of chicken and human liver is similar, we established a chicken model with carbon Tetrachloride- (CCl4-) induced fibrosis for studying antifibrotic effect of betaine in vivo and in vitro. Two-week-old male chicks were supplemented with betaine (1%, w/v) in drinking water for 2 weeks prior to the initiation of CCl4 treatment (i.p.) until sacrifice. Primary chicken hepatocytes were treated with CCl4 and betaine to mimic the in vivo supplementation. The supplementation of betaine significantly alleviated liver fibrosis development along with the inhibition of lipid peroxidation, hepatic inflammation cytokine, and transforming growth factor-β1 expression levels. These inhibitive effects were also accompanied with the attenuation of hepatic stellate cell activation. Furthermore, our in vitro studies confirmed that betaine provides antioxidant capacity for attenuating the hepatocyte necrosis by CCl4. Altogether, our results highlight the antioxidant ability of betaine, which alleviates CCl4-induced fibrogenesis process along with the suppression of hepatic stellate cells activation. Since betaine is a natural compound without toxicity, we suggest betaine can be used as a potent nutritional or therapeutic factor for reducing liver fibrosis.

1. Introduction

The prevalence of worldwide metabolic syndromes increases the incidence of chronic liver diseases including liver steatosis, steatohepatitis, fibrosis, and cirrhosis [1, 2]. In the progress of chronic liver diseases, liver fibrosis acts as a sign of liver damage and a factor of liver dysfunction by progressive cirrhosis in the liver [3]. Since the long periods of liver fibrosis progress, the therapies should be tolerable and safe for over decades. However, the therapeutic interventions of liver fibrosis have not been approved yet [4]. Therefore, the safe and well-tolerated natural compounds, which provide antifibrotic ability, might be an alternative choice until appropriate drug therapies become available.

Besides human, liver injury is also a common pathology in poultry, caused by many factors, such as nutrition, diseases, and toxins [5]. Furthermore, both human and chicken use liver for over 90% de novo lipogenesis [6, 7]. In rodents and rabbits, the adipose tissues and liver provide the equal function of de novo lipogenesis [8, 9]. Therefore, the chicken have been suggested and used as an animal model for human liver diseases recently [1012]. Although several studies described that the excessive hepatic lipogenesis and lipid accumulation are the very initiator of the liver fibrosis [2], liver fibrosis can also be a result of other liver injuries.

Liver fibrosis is the scarring process that represents liver injury and the excessive accumulation of collagen, which results from inflammation and the death of hepatocytes that occurs in most types of chronic liver diseases [3]. CCl4-induced liver injury is a commonly used rodent model to study liver pathologies, which shows similar morphology and the biochemical characteristic of the cellular lesions with human liver diseases [13]. Once exposed to CCl4, the cytochrome p450 2E1 (CYP2E1) in hepatocytes could metabolize CCl4 into trichloromethyl radicals (), which then induces lipid peroxidation and causes oxidative stress [14]. Numerous studies described that the elevation of cellular oxidative stress induces secretion of inflammatory cytokines, including interleukin- (IL-) 1, IL-6, and tumor necrosis factor (TNF) [15]. Furthermore, previous studies indicate that the inflammatory cytokines can regulate the secretion of transforming growth factor- (TGF-) β1, which is a cytokine involved in many cellular functions, including cell proliferation, differentiation, and apoptosis. Notably, TGF-β1 also plays a major role in the fibrogenesis process in response to liver injury, which contributes to a critical and fundamental event in hepatic fibrogenesis, known as hepatic stellate cells (HSCs) activation [16]. The activated HSCs are the mainly cell type involved in liver fibrosis, which forms scar tissue by producing collagens and extracellular matrix in response to liver damage [17, 18]. Hence, the HSCs have been suggested as a major target for the treatment of liver fibrosis.

Betaine is a naturally occurring compound found in common food, including wheat germ, bran, vegetables, and seafood [19]. Previous review indicates that the adult human takes 1.0–2.5 grams of betaine per day from dietary intake and suggests there is nontoxicity of betaine [20]. In mammalian metabolism, betaine has two major functions, acting as a major osmolyte in the brain and kidney to modulate cell volume [21, 22] and as a methyl group donor for the methionine-homocysteine cycle [23]. Besides the well-known cellular functions of betaine, previous studies have described that the exogenous betaine improves diets-induced fatty liver syndromes, cardiovascular diseases [20, 24], and against chemicals-induced liver fibrosis [25, 26]. Since the oxidative stress is a major factor in liver injury initiation [27], previous studies have suggested the hepatoprotective activity of betaine may be related to its antioxidant capacity to protect hepatocyte from free radicals [25, 28]. However, the knowledge of betaine alleviating liver fibrosis has yet to be clarified.

In the current study, we investigate the effects of betaine against liver fibrosis induced by CCl4 in chickens to evaluate the potential of therapy application. We also assessed the related mechanisms involved in antifibrotic effects of betaine.

2. Material and Methods

2.1. Animal and Experimental Design

Male Hy-line chicks at 1 d of age were purchased from a local hatchery. The chickens were fed with a standard diet and water ad libitum. The standard chicken growing diet was based on corn, soybean meal, and beef tallow and contained 18% protein, 2.5% fat, and 6% fiber with an energy content of 2800 kcal/kg. At 15 d of age, the chickens were divided into four groups (): (1) control (blank) group, (2) betaine group (drinking water containing 1% (w/v) betaine), (3) CCl4 group, and (4) CCl4-betaine group (drinking water containing 1% (w/v) betaine). Groups 1 and 2 chickens were injected with peanut oil (4.0 mL/kg. BW); groups 3 and 4 chickens were injected with CCl4 in peanut oil at a ratio of 1 : 1, v/v (4.0 mL/kg. BW). To induce liver fibrosis, CCl4 (or peanut oil for groups 1 and 2) was injected [5] into the pectoral muscle on experimental d1 (15 d of age) and d3. Each group of chickens was housed in independent compartments, and the environmental temperature and relative humidity were maintained in 25°C and 70%. Betaine (Sigma-B2629, Sigma-Aldrich, St. Louis, MO, USA) was given in the drinking water to group 2 and group 4 from experimental d1 to d14. The experimental design was shown in Figure 1.

On experimental d1 and d14, blood samples were collected from the carotid artery, and ethylenediaminetetraacetic acid was used as anticoagulant. Samples were centrifuged at 2,000 ×g for 10 min to collect plasma. Chickens were killed by carbon dioxide to harvest the livers on experimental d14. A portion of the liver was fixed in 10% formaldehyde for histology analysis. Another portion of the liver was frozen in liquid nitrogen and stored at −80°C. All procedures were approved by the Institutional Animal Care and Use Committee of National Taiwan University.

2.2. Biochemical Analysis

Plasma was diluted with 0.9% (w/v) NaCl and analyzed for alanine aminotransferase (ALT; AL1268, RANDOX, Antrim, UK) and aspartate aminotransferase (AST; AS101, RANDOX, Antrim, UK) by colorimetric end point assays according to the manufacturer’s instructions. Liver 8-hydroxy-2-deoxyguanosine (8-OHdG; MBS261211, MyBioSources, Inc., San Diego, CA, USA) and plasma dipeptidyl-peptidase 4 (DPP4; MBS023397, MyBioSources, Inc., San Diego, CA, USA) and glutathione S-transferase (GST; MBS743037, MyBioSources, Inc., San Diego, CA, USA) concentrations were measured with chicken-specific ELISA kits according to the manufacturer’s instructions.

The liver malondialdehyde (MDA) assay was used to assess degree of lipid peroxidation. It was measured by thiobarbituric acid test described in the previous study [29]. The betaine concentrations in chicken liver were measured by colorimetric method, as described previously, with minor modifications [30]. In briefly, the betaine can be deposited by ammonium Reinecke salt in acidic environment (pH 1.0), the deposited-complex could dissolve in 70% acetone, and the absorbance of the colored-solutions was measured at 525 nm.

2.3. Histology Analysis

Livers were fixed in 10% buffered formaldehyde, embedded in paraffin, sectioned at 5 μm, and stained with Masson’s trichrome stain to examine the existence of liver fibrosis, that is, collagen deposition. Stained liver sections were analyzed using ImageJ software (NIH, Bethesda, MD, USA).

2.4. Quantitative Real-Time PCR

Total RNA was extracted from frozen liver tissue samples using TRIzol (Invitrogen Carlsbad, CA, USA). The TURBO DNA-free kit (Invitrogen Carlsbad, CA, USA) was utilized to remove the contamination of genomic DNA. mRNA was then reverse transcribed to cDNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative real-time PCR reactions were performed on a StepOne Plus real-time PCR System (Applied Biosystems, Foster City, CA, USA) using a DyNAmo Flash SYBR Green kit (Finnzymes, Espoo, Finland). Running conditions for real-time PCR were initial denaturation at 95°C for 7 min and denaturation at 95°C for 10 s, annealing at appropriate temperature for each pair of primers and extension for 30 s for a total of 38 cycles. Finally, there was an extension time of 30 s at 72°C. The primer sequences and annealing temperatures were listed in Table 1. Threshold cycle (Ct) values were obtained and relative gene expression was calculated using the formula [31]. The β-actin mRNA was measured in each sample by real-time quantitative PCR as a reference gene and levels of mRNA were expressed as a ratio with reference to the expression of β-actin.

Gene symbolPrimer sequences 5′-3′Anneal temp. (°C)GenBank accession numberProduct size (bp)












IL-6, interleukin-6; TGF-β1, transforming growth factor-β1; ACTA2, α-smooth muscle actin; COL1A1, collagen type 1-α1; COL3A1, collagen type 3-α1; DPP4, dipeptidyl-peptidase 4; GST, glutathione S-transferase; DDT, d-dopachrome tautomerase; GLUL, glutamine synthetase; AACS, acetoacetyl-CoA synthase; and ACTB, β-actin.
2.5. Cell Isolation and Culture

Chicken hepatocytes were isolated from the one week old Hy-line male chicks [32]. Hepatocytes were plated in 6-well plates containing 2 mL Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen Carlsbad, CA, USA) with 10% chicken serum (Invitrogen Carlsbad, CA, USA) and 100 U penicillin/mL, 100 mg streptomycin/mL, and 1.5 μg/mL amphotericin B. Cells were cultured at 37°C in air containing 5% CO2. Each well contained 1 × 105 cells; incubations were continued until the cells reached 80 to 90% confluence. Then, the medium was removed and replaced with serum-free DMEM for 24 h. After the serum-free period, primary hepatocytes were treated with or without 5 mM CCl4 for 20 h to induce hepatocyte necrosis, and different concentrations of betaine (0, 5, 10, or 20 mM) were cotreated at the same time to test the betaine as an antifibrosis agent. After incubation, cells and medium were harvested for analysis.

2.6. Cell Survival

After 20 h exposure to betaine (0, 5, 10, or 20 mM) ± CCl4 (0 or 5 mM) to induce cell necrosis in chicken primary hepatocytes, cell viability was measured by using the tetrazolium, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (M5655, Sigma-Aldrich, St. Louis, MO, USA) assay [33].

2.7. Statistical Analysis

All results were expressed as means ± SEM. Statistical analysis was by two-way ANOVA, and means from groups with a significant ANOVA were separated using Tukey’s test for statistical difference. Differences between treatments were considered to be statistically significant at .

3. Results

3.1. General Findings

The general findings of the chicken at the age of d14 are shown in Table 2. No significant differences were observed in the body weight between control, betaine, and CCl4 groups. Only CCl4-betaine group had significant lower body weight than control group. In the relative liver weights, the CCl4-betaine group was significantly increased in comparison with other groups. To evaluate the effect of betaine on CCl4-induced liver injury, plasma AST and ALT were measured on d14. Notably, no significant differences in the plasma AST and ALT levels between each group were observed. The no changes of plasma AST and ALT levels are in agreement with previous studies that plasma AST and ALT are inefficient liver injury biomarkers in poultry [34, 35].


Body weights (g)60.766 ± 1.03058.515 ± 0.62661.890 ± 0.75854.146 ± 0.838
Relative liver weight (%)2.804 ± 0.0903.177 ± 0.0522.670 ± 0.0333.4122 ± 0.097

Plasma parameters:
 AST (IU/L)81.364 ± 8.63563.372 ± 6.02384.310 ± 11.50078.266 ± 4.017
 ALT (IU/L)3.492 ± 0.9433.543 ± 0.5342.968 ± 0.8102.729 ± 0.398

Values were presented as the mean ± SEM. Data were analyzed by two-way ANOVA (). Means with the same letter were not significantly different ().
3.2. Effects of Betaine on Liver Fibrosis Development

We first examined the effects of betaine on liver fibrosis induced by CCl4. The abnormal collagen deposition is one of special characters of liver fibrosis [3]. Under Masson’s trichrome staining, the markedly increased collagen deposition was discovered in the CCl4 group; addition of betaine with the CCl4 treatment significantly suppressed liver fibrosis in comparison with CCl4 group, and no fibrosis was found in the control or betaine groups (Figure 2(a)). The quantitative analysis showed that collagen deposition drastically decreased by exposure to betaine in comparison with CCl4 group (Figure 2(b)). The concentration of betaine in the liver with betaine group was significantly higher than CCl4-betaine group and control group (Figure 2(b)). To determine the changes of oxidative stress by betaine supplementation, the 8-OHdG and MDA levels of livers were measured to assess oxidative stress and lipid peroxidation; stimulation of CCl4 greatly increased 8-OHdG and MDA levels, and supplementation of betaine significantly decreased this response (Figures 2(d)-2(e)).

To quantitate the effects of betaine on CCl4-induced fibrogenesis, we examined the mRNA expression levels of IL-6, TGF-β1, ACTA2, COL1A1, and COL3A1 in chicken livers; each of these genes represents different steps of liver fibrosis developing progress, whereas IL-6 represents the inflammation in respond to CCl4 stimulation in liver [36]; TGF-β1 as a key cytokine is involved in the pathogenesis of fibrosis in liver and the initiator of activated HSCs [16]; ACTA2 also known as alpha smooth muscle actin (α-SMA) is a marker of activated HSCs [37]; types I and III collagen mRNA (COL1A1 and COL3A1) expression levels represent collagen productions in HSCs [38]. In our study, each gene’s expression levels were increased by CCl4 injection, and the attenuated elevation of these gene expressions was discovered in betaine supplementation group (Figure 3). These results indicate that the antifibrotic effect of betaine might be provided by its antioxidant capacity. Furthermore, betaine might also affect the progression of liver fibrosis by suppressing activation of HSCs.

3.3. Effects of Betaine on Selected Liver Injury Biomarkers of Chicken

As noted above, the mammalian liver injury biomarkers (AST and ALT) are inefficient in poultry [34, 35]. Unsurprisingly, current data showed CCl4-induced serious liver fibrosis did not significantly change the plasma AST and ALT levels in the present study (Table 2). For diagnosing liver injury levels of chickens, recently, our groups screened the chicken liver injury biomarkers through transcriptome and proteome analysis and found several useful biomarkers for liver fibrosis (unpublished observations). These biomarkers are acetoacetyl-CoA synthetase (AACS), dipeptidyl-peptidase 4 (DPP4), d-dopachrome tautomerase (DDT), glutamine synthetase (GLUL), and glutathione S-transferase (GST); particularly, the plasma DPP4 and GST levels were highly associated with CCl4-induced liver fibrosis. Here, we examined the mRNA expression levels of these chicken liver injury biomarkers and plasma DPP4 and GST concentrations in each group. CCl4 injection increased expressions of DPP4, GST, DDT, and GLUL (Figure 4(a)). We observed exposure of chickens to betaine could reverse these increments in DPP4, GST, and DDT expression levels (Figure 4(a)). Further, the plasma DPP4 and GST concentrations also followed the pattern of the mRNAs, DPP4 showed 1.6-fold decrease, and GST showed 1.3-fold decrease in CCl4-betaine group compared with CCl4 group (Figures 4(b)-4(c)). These results indicated the screening biomarkers from the current study were more effective than AST and ALT. Furthermore, the current results showed the antifibrotic effects of betaine were accompanied by decreasing gene expressions of screening biomarkers and plasma DPP4 and GST concentrations.

3.4. Betaine Affected Necrosis, Lipid Peroxidation, and Inflammation in Chicken Hepatocytes In Vitro

We observed betaine treatment decreased the CCl4-stimulated 8-OHdG and MDA levels in the liver (Figures 2(d)-2(e)), suggesting that hepatic injury caused by CCl4 was alleviated by betaine, possibly because of its antioxidant properties. To confirm this speculation, we isolated chicken primary hepatocytes and examined the hepatocyte necrosis, lipid peroxidation, and inflammation within CCl4 and betaine treatments. In CCl4-treated hepatocytes, the cell survival ratio was significantly decreased. The cell survival ratio showed a reversed response in a dosage-dependent manner with betaine supplementation (Figure 5(a)). As in vivo data, the significantly elevated lipid peroxidation (measured by MDA concentration in the cell culture medium) was found in chicken primary hepatocytes exposed to CCl4, and this effect was also rescued by betaine treatment in a dosage-dependent manner (Figure 5(b)). We further examined the expression levels of IL-6 and TGF-β1 in chicken primary hepatocytes. Similar to the results of cell survival ratio and MDA levels, both IL-6 and TGF-β1 expression levels were increased by exposing CCl4, and these increments were also inhibited by betaine supplementation in a dosage-dependent manner (Figures 5(c)-5(d)). Taken together, these results suggested that the hepatoprotective effect of betaine is derived from suppressing CCl4-induced oxidative stress along with decreasing inflammation and activation of HSCs.

4. Discussion

Betaine is distributed broadly in plants, animals, and microorganisms and also rich in dietary sources [20]. In mammalian, the major physiologic functions of betaine are as an osmotic regulator and methyl group donor for the methionine-homocysteine cycle [23]. Previous studies indicate betaine could activate AMP-activated protein kinase to reduce lipid synthesis and fat accumulation in the liver to improve nonalcoholic fatty liver disease [39, 40]. In other liver injury studies, betaine also provides hepatoprotective effects against several hepatotoxicants such as CCl4, ethanol, lipopolysaccharide, α-naphthylisothiocyanate, and dimethyl nitrosamine [2426, 41, 42]. Previous review of betaine concludes the betaine is safe at a daily intake of 9–15 g [20]. In addition, the nontoxicity of betaine (0–5% of the diet) has also been reported in subacute and subchronic rat studies [43]. Collectively, these studies suggest the supplementation of betaine could be a potential therapeutic strategy for liver diseases.

As noted above, HSCs have been suggested as the central factor of the overabundance of collagen and extracellular matrix production in liver fibrosis. In the progression of liver fibrosis, the activation of HSCs regulates the proliferation of HSCs. Previous studies demonstrate the proliferation and activation of HSCs are associated with the oxidative stress, which results from the increased production of lipid peroxidation and reactive oxygen species [3, 44]. Therefore, the antioxidant capacity is recognized as one of the critical therapeutic interventions of liver fibrosis.

In this study, we firstly examined that betaine could provide antifibrotic effects on CCl4-induced liver fibrosis in chickens. The histological detection provides the evidence of betaine suppressing the CCl4-induced collagen deposition. In vitro data confirmed that betaine could rescue the CCl4-induced hepatocyte necrosis. Previous study has indicated the supplementation of betaine could protect the lipopolysaccharide-induced hepatic necrosis by suppressing Kupffer cell activation and acting as an antioxidant [45]. For evaluating the antioxidant capacity of betaine, we examined the oxidative stress induced by CCl4, which showed a significant decreasing by treatment of betaine in both in vivo and in vitro studies. As far as the antioxidants exert anti-inflammatory activities [46], we also examined the anti-inflammatory ability of betaine by detecting the IL-6 expression in liver and primary hepatocyte. Betaine supplementations significantly decreased the CCl4-stimulated IL-6 expression levels both in vivo and in vitro. As previous studies described, inflammatory cytokines and TGF-β1 showed interactions during the disease state. In liver fibrosis, TGF-β1 is one of the most crucial cytokines, which stimulates hepatic fibrogenesis through TGF-β1/Smad signaling pathway in activated HSCs. In activated HSCs, the upregulated TGF-β receptors induce the formation of Smad complex. This Smad complex then translocates into nucleus and regulates the transcription of collagens [16]. In our study, we showed that treatment with betaine suppressed the mRNA expression of TGF-β1, which was induced by CCl4 both in vivo and in vitro. Besides, the activation of HSCs and collagen synthesis were assessed by ACTA2, COL1A1, and COL3A1 mRNA expression levels, which were also suppressed by betaine supplementation. Thus, we hypothesized that betaine may not only reduce the oxidative stress but probably also suppress the activation and functions of HSCs.

To verify whether betaine can directly alter the activation and functions of HSCs, we isolated chicken HSCs following Yata et al. [47]. The HSCs were stimulated with TGF-β1 and cotreated with betaine. We examined whether betaine directly suppressed the TGF-β1-dependents HSCs activation and collagen synthesis by detecting ACTA2, DPP4, COL1A1, and COL3A1 mRNA expression levels and total collagen in the HSCs. As shown in supplementary Figure 1 (see Supplementary Material available online at http://dx.doi.org/10.1155/2015/725379), all these genes and total collagen contents were not altered by treatment of betaine, which indicates that the betaine cannot directly affect HSCs but provides the antioxidant capacity to reduce the oxidative stress on hepatocytes.

In human studies, elevated plasma levels of AST and ALT and increased ratio of AST/ALT (>1) work as biomarkers for liver injuries and alcoholic liver diseases [4850]. However, the previous studies observed the inefficiency of AST and ALT in avian liver injury [34, 35], but some could detect the significant difference in avian liver injury [5]. Based on these inconsistent results, our previous study has suggested plasma DPP4 and GST concentration could serve as good potential biomarkers of chicken liver injury (unpublished data). As expected, we observed significant increasing in the plasma concentrations of DPP4 and GST by CCl4 stimulation, and supplementation of betaine alleviated these abnormal increments. There is a high association between serum DPP4 activity and liver injury in the rat [51]. Interestingly, previous studies demonstrate that DPP4 is only expressed in Ac-HSCs [52] and suggest inhibition of DPP4 activity could reduce hepatic fibrosis through suppression of HSCs proliferation and collagen synthesis [53]. These studies indicate the critical role of DPP4 in liver fibrosis progression, whereas DPP4-inhibitor has also been suggested to be a potential therapeutic agent for liver fibrosis [53]. In the present study, we firstly found the significant amelioration of liver fibrosis was accompanied with the decrement of DPP4 hepatic gene expression and plasma DPP4 concentrations when treated with betaine. Previous study has described that DPP4-inhibitor could suppress TGF-β1 signaling pathways (Smad2/3 and ERK1/2), which regulate the collagens synthesis and HSCs proliferation [16]. In our study, we also found that betaine treatment suppressed expression of TGF-β1, activation of HSCs, and collagen formation in the liver. Collectively, the results of DPP4 provided evidence that betaine treatment suppressed the activation of HSCs.

The other liver injury biomarker, GST, can function through catalyzing the conjugation of the antioxidant, glutathione, which detoxifies endogenous compounds including peroxidised lipids and xenobiotics [54, 55]. In the present study, hepatic GST gene expression and plasma concentrations of GST showed increments under CCl4 stimulation, and these increments were reversed by betaine supplementation. The elevated plasma GST concentration in response to CCl4 stimulation may represent a defense mechanism in the hepatocytes to combat lipid peroxidation by producing more glutathione. These effects confirmed the antioxidant capacity of betaine in coping with CCl4-induced oxidative stress.

5. Conclusion

In summary, we demonstrated the treatment with betaine evidently suppressed liver fibrosis along with alleviation of lipid peroxidation, inflammation, and activation of HSCs. These beneficial effects of betaine might associate with its antioxidant ability, which is against CCl4-induced cell necrosis and lipid peroxidation. Based on the results, we hypothesized a possible mechanism scheme of betaine against liver fibrosis in Figure 6. Because the chicken has potential to be a human liver disease model and based on the significant antifibrotic effects of betaine in CCl4-induced liver fibrosis, we suggested that betaine may represent a potent therapeutic agent for liver fibrosis.

Conflict of Interests

This publication contains only academic research results. The authors declare there is no conflict of interests in any way.

Authors’ Contribution

Meng-Tsz Tsai and Shih-Torng Ding conceived the research and Ching-Yi Chen provided the consultation. Meng-Tsz Tsai performed the experiments and was assisted by Yu-Hui Pan and Siou-Huei Wang. The paper was written and revised by Meng-Tsz Tsai, Harry J. Mersmann, and Shih-Torng Ding. All authors critically reviewed the paper and agreed the final submitted paper.


The study was supported by a grant from the Ministry of Science and Technology in Taiwan.

Supplementary Materials

To clarify whether betaine can directly suppress the activation of HSCs, we isolated the primary chicken HSCs, stimulated with TGF-β1 and co-treated with different concentrations of betaine. First, we detected the total collagen concentration in the HSCs culture medium, the results showed betaine supplementation did not suppress TGF-β1-stimualted collagen secretion (Figure S1 a). Furthermore, to confirm the effect of betaine on TGF--β1-activated HSCs, we used real-rime PCR to detect the expression of HSCs activation and collagen synthesis related genes (ACTA2, DPP4, COL1A1 and COL3A1). The result of collagen content in the culture medium indicated that the betaine supplementation cannot suppressed the TGF-β1-evelvated gene expressions. These results suggested treatments of betaine cannot directly suppress TGF-β1-stimulated HSCs activation and collagen synthesis.

  1. Supplementary Material


  1. R. V. Farese Jr., R. Zechner, C. B. Newgard, and T. C. Walther, “The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance,” Cell Metabolism, vol. 15, no. 5, pp. 570–573, 2012. View at: Publisher Site | Google Scholar
  2. D. J. Chiang, M. T. Pritchard, and L. E. Nagy, “Obesity, diabetes mellitus, and liver fibrosis,” The American Journal of Physiology–Gastrointestinal and Liver Physiology, vol. 300, no. 5, pp. G697–G702, 2011. View at: Publisher Site | Google Scholar
  3. R. Bataller and D. A. Brenner, “Liver fibrosis,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005. View at: Publisher Site | Google Scholar
  4. D. Schuppan and Y. O. Kim, “Evolving therapies for liver fibrosis,” The Journal of Clinical Investigation, vol. 123, no. 5, pp. 1887–1901, 2013. View at: Publisher Site | Google Scholar
  5. C. Wang, T. Zhang, X. Cui, S. Li, X. Zhao, and X. Zhong, “Hepatoprotective effects of a chinese herbal formula, longyin decoction, on carbon-tetrachloride-induced liver injury in chickens,” Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 392743, 9 pages, 2013. View at: Publisher Site | Google Scholar
  6. G. A. Leveille, E. K. O'Hea, and K. Chakbabarty, “In vivo lipogenesis in the domestic chicken,” Proceedings of the Society for Experimental Biology and Medicine, vol. 128, no. 2, pp. 398–401, 1968. View at: Google Scholar
  7. D. J. Galton, “Lipogenesis in human adipose tissue,” Journal of Lipid Research, vol. 9, no. 1, pp. 19–26, 1968. View at: Google Scholar
  8. G. P. Laliotis, I. Bizelis, and E. Rogdakis, “Comparative approach of the de novo fatty acid synthesis (lipogenesis) between ruminant and non ruminant mammalian species: from biochemical level to the main regulatory lipogenic genes,” Current Genomics, vol. 11, no. 3, pp. 168–183, 2010. View at: Publisher Site | Google Scholar
  9. M. K. Hellerstein, “No common energy currency: de novo lipogenesis as the road less traveled,” The American Journal of Clinical Nutrition, vol. 74, no. 6, pp. 707–708, 2001. View at: Google Scholar
  10. I. Ayala, A. M. Castillo, G. Adánez, A. Fernández-Rufete, B. G. Pérez, and M. T. Castells, “Hyperlipidemic chicken as a model of non-alcoholic steatohepatitis,” Experimental Biology and Medicine, vol. 234, no. 1, pp. 10–16, 2009. View at: Publisher Site | Google Scholar
  11. D. J. Kudzma, P. M. Hegstad, and R. E. Stoll, “The chick as a laboratory model for the study of estrogen-induced hyperlipidemia,” Metabolism, vol. 22, no. 3, pp. 423–434, 1973. View at: Publisher Site | Google Scholar
  12. P. Makovicky, M. Dudova, E. Tumova, R. Rajmon, and Z. Vodkova, “Experimental study of non-alcoholic fatty liver disease (NAFLD) on a model of starving chickens: is generalization of steatosis accompanied by fibrosis of the liver tissue?” Pathology Research and Practice, vol. 207, no. 3, pp. 151–155, 2011. View at: Publisher Site | Google Scholar
  13. R. Perez Tamayo, “Is cirrhosis of the liver experimentally produced by CC14 an adequate model of human cirrhosis?” Hepatology, vol. 3, no. 1, pp. 112–120, 1983. View at: Google Scholar
  14. L. Knockaert, A. Berson, C. Ribault et al., “Carbon tetrachloride-mediated lipid peroxidation induces early mitochondrial alterations in mouse liver,” Laboratory Investigation, vol. 92, no. 3, pp. 396–410, 2012. View at: Publisher Site | Google Scholar
  15. S. Reuter, S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, “Oxidative stress, inflammation, and cancer: how are they linked?” Free Radical Biology and Medicine, vol. 49, no. 11, pp. 1603–1616, 2010. View at: Publisher Site | Google Scholar
  16. A. Leask and D. J. Abraham, “TGF-β signaling and the fibrotic response,” The FASEB Journal, vol. 18, no. 7, pp. 816–827, 2004. View at: Publisher Site | Google Scholar
  17. P. Starkel and I. A. Leclercq, “Animal models for the study of hepatic fibrosis,” Best Practice and Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 319–333, 2011. View at: Publisher Site | Google Scholar
  18. S. Das, A. Santra, S. Lahiri, and D. N. G. Mazumder, “Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity,” Toxicology and Applied Pharmacology, vol. 204, no. 1, pp. 18–26, 2005. View at: Publisher Site | Google Scholar
  19. S. H. Zeisel, M.-H. Mar, J. C. Howe, and J. M. Holden, “Concentrations of choline-containing compounds and betaine in common foods,” The Journal of Nutrition, vol. 133, no. 5, pp. 1302–1307, 2003. View at: Google Scholar
  20. S. A. S. Craig, “Betaine in human nutrition,” The American Journal of Clinical Nutrition, vol. 80, no. 3, pp. 539–549, 2004. View at: Google Scholar
  21. M. Lever and S. Slow, “The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism,” Clinical Biochemistry, vol. 43, no. 9, pp. 732–744, 2010. View at: Publisher Site | Google Scholar
  22. F. Lang, “Mechanisms and significance of cell volume regulation,” Journal of the American College of Nutrition, vol. 26, no. 5, pp. 613S–623S, 2007. View at: Google Scholar
  23. A. Bidulescu, L. E. Chambless, A. M. Siega-Riz, S. H. Zeisel, and G. Heiss, “Usual choline and betaine dietary intake and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study,” BMC Cardiovascular Disorders, vol. 7, article 20, 2007. View at: Publisher Site | Google Scholar
  24. A. J. Barak, H. C. Beckenhauer, and D. J. Tuma, “Betaine, ethanol, and the liver: a review,” Alcohol, vol. 13, no. 4, pp. 395–398, 1996. View at: Publisher Site | Google Scholar
  25. F. Erman, J. Balkan, U. Çevikbaş, N. Koçak-Toker, and M. Uysal, “Betaine or taurine administration prevents fibrosis and lipid peroxidation induced by rat liver by ethanol plus carbon tetrachloride intoxication,” Amino Acids, vol. 27, no. 2, pp. 199–205, 2004. View at: Publisher Site | Google Scholar
  26. S. K. Kim, J. M. Seo, Y. R. Chae, Y. S. Jung, J. H. Park, and Y. C. Kim, “Alleviation of dimethylnitrosamine-induced liver injury and fibrosis by betaine supplementation in rats,” Chemico-Biological Interactions, vol. 177, no. 3, pp. 204–211, 2009. View at: Publisher Site | Google Scholar
  27. M. A. Lozovoy, A. N. Simão, C. Panis et al., “Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus,” Lupus, vol. 20, no. 12, pp. 1250–1259, 2011. View at: Publisher Site | Google Scholar
  28. M. Alirezaei, H. R. Gheisari, V. R. Ranjbar, and A. Hajibemani, “Betaine: a promising antioxidant agent for enhancement of broiler meat quality,” British Poultry Science, vol. 53, no. 5, pp. 699–707, 2012. View at: Publisher Site | Google Scholar
  29. H. Ohkawa, N. Ohishi, and K. Yagi, “Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction,” Analytical Biochemistry, vol. 95, no. 2, pp. 351–358, 1979. View at: Publisher Site | Google Scholar
  30. R. L. Focht, F. H. Schmidt, and B. B. Dowling, “Colorimetric determination of betaine in glutamate process end liquor,” Journal of Agricultural and Food Chemistry, vol. 4, no. 6, pp. 546–548, 1956. View at: Publisher Site | Google Scholar
  31. T. D. Schmittgen, B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and M. W. Reed, “Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods,” Analytical Biochemistry, vol. 285, no. 2, pp. 194–204, 2000. View at: Publisher Site | Google Scholar
  32. D.-X. Hou, T. Kunitake, J. Kusuda, and M. Fujii, “Primary culture of chicken hepatocytes as an in vitro model for determining the influence of dioxin,” Bioscience, Biotechnology and Biochemistry, vol. 65, no. 1, pp. 218–221, 2001. View at: Publisher Site | Google Scholar
  33. A. A. van de Loosdrecht, R. H. J. Beelen, G. J. Ossenkoppele, M. G. Broekhoven, and M. M. A. C. Langenhuijsen, “A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia,” Journal of Immunological Methods, vol. 174, no. 1-2, pp. 311–320, 1994. View at: Publisher Site | Google Scholar
  34. G. J. Diaz, E. J. Squires, and R. J. Julian, “The use of selected plasma enzyme activities for the diagnosis of fatty liver-hemorrhagic syndrome in laying hens,” Avian Diseases, vol. 43, no. 4, pp. 768–773, 1999. View at: Publisher Site | Google Scholar
  35. S. T. Ferrell, “Avian integumentary surgery,” Seminars in Avian and Exotic Pet Medicine, vol. 11, no. 3, pp. 125–135, 2002. View at: Publisher Site | Google Scholar
  36. A. Salazar-Montes, A. R. Rincón, A. Panduro, and J. Armendáriz-Borunda, “Chemically induced liver regeneration is characterized by specific IL-6 gene expression,” Hepatology Research, vol. 15, no. 1, pp. 10–21, 1999. View at: Publisher Site | Google Scholar
  37. I. Mannaerts, N. R. Nuytten, V. Rogiers, K. Vanderkerken, L. A. Van Grunsven, and A. Geerts, “Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cells in vitro and in vivo,” Hepatology, vol. 51, no. 2, pp. 603–614, 2010. View at: Publisher Site | Google Scholar
  38. W.-B. Liu, C.-Q. Yang, W. Jiang et al., “Inhibition on the production of collagen type I, III of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid,” World Journal of Gastroenterology, vol. 9, no. 2, pp. 316–319, 2003. View at: Google Scholar
  39. Z. Song, I. Deaciuc, Z. Zhou et al., “Involvement of AMP-activated protein kinase in beneficial effects of betaine on high-sucrose diet-induced hepatic steatosis,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 293, no. 4, pp. G894–G902, 2007. View at: Publisher Site | Google Scholar
  40. E. Kathirvel, K. Morgan, G. Nandgiri et al., “Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 299, no. 5, pp. G1068–G1077, 2010. View at: Publisher Site | Google Scholar
  41. Y. S. Jung, S. J. Kim, D. Y. Kwon et al., “Alleviation of alcoholic liver injury by betaine involves an enhancement of antioxidant defense via regulation of sulfur amino acid metabolism,” Food and Chemical Toxicology, vol. 62, pp. 292–298, 2013. View at: Publisher Site | Google Scholar
  42. S. K. Kim and Y. C. Kim, “Effects of betaine supplementation on hepatic metabolism of sulfur-containing amino acids in mice,” Journal of Hepatology, vol. 42, no. 6, pp. 907–913, 2005. View at: Publisher Site | Google Scholar
  43. K. C. Hayes, A. Pronczuk, M. W. Cook, and M. C. Robbins, “Betaine in sub-acute and sub-chronic rat studies,” Food and Chemical Toxicology, vol. 41, no. 12, pp. 1685–1700, 2003. View at: Publisher Site | Google Scholar
  44. G. Poli, “Pathogenesis of liver fibrosis: role of oxidative stress,” Molecular Aspects of Medicine, vol. 21, no. 3, pp. 49–98, 2000. View at: Publisher Site | Google Scholar
  45. J. Balkan, F. H. Parildar, S. Dogru-Abbasoglu, G. Aykac-Toker, and M. Uysal, “The effect of taurine or betaine pretreatment on hepatotoxicity and prooxidant status induced by lipopolysaccharide treatment in the liver of rats,” European Journal of Gastroenterology and Hepatology, vol. 17, no. 9, pp. 917–921, 2005. View at: Publisher Site | Google Scholar
  46. R. F. Grimble, “Nutritional antioxidants and the modulation of inflammation: theory and practice,” New Horizons, vol. 2, no. 2, pp. 175–185, 1994. View at: Google Scholar
  47. Y. Yata, S. Enosawa, S. Suzuki et al., “An improved method for the purification of stellate cells from rat liver with dichloromethylene diphosphate (CL2MDP),” Methods in Cell Science, vol. 21, no. 1, pp. 19–24, 1999. View at: Publisher Site | Google Scholar
  48. A. J. Sanyal, “AGA technical review on nonalcoholic fatty liver disease,” Gastroenterology, vol. 123, no. 5, pp. 1705–1725, 2002. View at: Publisher Site | Google Scholar
  49. H. Nyblom, U. Berggren, J. Balldin, and R. Olsson, “High AST/ALT ratio may indicate advanced alcoholic liver disease rather than heavy drinking,” Alcohol and Alcoholism, vol. 39, no. 4, pp. 336–339, 2004. View at: Publisher Site | Google Scholar
  50. P. Angulo, J. M. Hui, G. Marchesini et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, vol. 45, no. 4, pp. 846–854, 2007. View at: Publisher Site | Google Scholar
  51. G. Firneisz, T. Varga, G. Lengyel et al., “Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker,” PLoS ONE, vol. 5, no. 8, Article ID e12226, 2010. View at: Publisher Site | Google Scholar
  52. M. T. Levy, G. W. McCaughan, C. A. Abbott et al., “Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis,” Hepatology, vol. 29, no. 6, pp. 1768–1778, 1999. View at: Publisher Site | Google Scholar
  53. K. Kaji, H. Yoshiji, Y. Ikenaka et al., “Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats,” Journal of Gastroenterology, vol. 49, no. 3, pp. 481–491, 2014. View at: Publisher Site | Google Scholar
  54. R. Sharma, Y. Yang, A. Sharma, S. Awasthi, and Y. C. Awasthi, “Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis,” Antioxidants and Redox Signaling, vol. 6, no. 2, pp. 289–300, 2004. View at: Publisher Site | Google Scholar
  55. D. M. Townsend and K. D. Tew, “The role of glutathione-S-transferase in anti-cancer drug resistance,” Oncogene, vol. 22, no. 47, pp. 7369–7375, 2003. View at: Publisher Site | Google Scholar

Copyright © 2015 Meng-Tsz Tsai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.